01 July 2009
By:Eric S. Langer
Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized.
 |
01 June 2009
By:Eric Langer
There may well be a pending revolution in biopharmaceutical expression systems. Nearly 50% of biomanufacturers today are demanding a whole lot more from their primary expression systems than they have during the past 30 years.
|
29 May 2009
Thanks to advances in synthesis, delivery and formulation, the number of therapeutic peptides entering clinical trials this decade is almost double the rate of the 1990s, and investment in new therapeutic peptide product development is expected to continue at a strong pace for the foreseeable future.
|
29 May 2009
A study has identified the innovative strength of more than 30 countries when it comes to biotechnology. Who came out on top?
|
01 May 2009
By:Susan Aldridge
The identification of an increasing number of drug targets coupled with advances in manufacturing technology could lead to many more blockbuster therapeutic antibodies.
|
01 April 2009
By:Xuemin Liu, Mike Collins, Nathalie Fraud, Jennifer Campbell, Inese Lowenstein, Karol M. Lacki, Anurag Rathore
The number of biotechnology-based human therapeutic products in the late-stage pipeline along with the average cost to commercialize a biotech product has been steadily increasing with time. In addition, the biotech industry is facing unprecedented challenges of a sagging global economy and rising regulatory expectations. Companies have to continue to evolve their approaches to be more efficient with respect to time, resources and cost. This article describes some of the technologies that can help optimize time and cost of biopharmaecutical manufacturing.
|
01 March 2009
Michiel Ultee talks about the challenges involved in transferring technology to a CMO and why communication is so important.
|
01 March 2009
By:Faiz Kermani
The productivity of the pharma industry has been declining for several years. Could biotechnology reinvigorate drug development?
|
01 March 2009
By:Michael Kraft, George Barringer
PAT guidance has been available from FDA for more than 4 years, but there have been no apparent breakthroughs in large-scale upstream production. Will companies consider using on?line chromatography to change this?
|
| 
